Natco reported strong Sept 24 quarterly results. Reported total revenue of INR 1434.9 Crore for the second quarter of FY2025 that ended on 30th Sept 2024, as against INR 1060.8 Crore for the same period last year, reflecting a growth of 35.3%. The net profit for the period, on a consolidated basis, was INR 676.5 Crore as against INR 369.0 Crore same period last year, showing robust growth of about 83%.
As per Investor presentation, key Para IV pipeline now includes Tabrecta (Capmatinib) as sole FTF and Jevtana (Cabazitaxel) as shared FTF, tried figuring out the opportunity size in US, but unable to get the relevant data.
If anyone in valuepickr board have insights on the size of these opportunities, pls share. Thanks
| Subscribe To Our Free Newsletter |
